Precision medicine for disease modification in Parkinson disease

Nature Reviews Neurology

Volumn 13, Issue 2, 2017, Pages 119-126

  Espay, Alberto J ^a   Brundin, Patrik ^b   Lang, Anthony E ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

9,12 EPOXY 5,16 BIS[(ETHYLTHIO)METHYL] 2,3,9,10,11,12 HEXAHYDRO 10 HYDROXY 9 METHYL 1 OXO 1H DIINDOLO[1,2,3 FG:3',2',1' KL]PYRROLO[3,4 I][1,6]BENZODIAZOCINE 10 CARBOXYLIC ACID METHYL ESTER; ALPHA SYNUCLEIN; ANTIOXIDANT; COGANE; CREATINE; GPI 1485; LEUCINE RICH REPEAT KINASE 2; LIATERMIN; MINOCYCLINE; MITOQUINONE; NEURTURIN; OMIGAPIL; PALIRODEN; PIOGLITAZONE; RASAGILINE; RECOMBINANT GROWTH FACTOR; RILUZOLE; SELEGILINE; TOCOPHEROL; UBIDECARENONE; UNCLASSIFIED DRUG;

COHORT ANALYSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; EPIGENETICS; GAIT DISORDER; HUMAN; LRRK2 GENE; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POPULATION RESEARCH; POSTURAL INSTABILITY GAIT DISORDER; PRODROMAL SYMPTOM; PURE AUTONOMIC FAILURE; REVIEW; GENETICS; PATHOLOGY;

HUMANS; PARKINSON DISEASE; PRECISION MEDICINE;

EID: 85009962474     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.196     Document Type: Review

References (67)

1. Kalia, L. V., Kalia, S. K. & Lang, A. E. Disease-modifying strategies for Parkinson's disease. Mov. Disord. 30, 1442-1450 (2015).
2. Calne, D. B. & Mizuno, Y. The neuromythology of Parkinson's Disease. Parkinsonism Relat. Disord. 10, 319-322 (2004).
3. Berg, D. et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord. 29, 454-462 (2014).
4. Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30, 1591-1601 (2015).
5. Berg, D. et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol. 12, 514-524 (2013).
6. Willis, A. W. et al. Predictors of survival in patients with Parkinson disease. Arch. Neurol. 69, 601-607 (2012).
7. Munhoz, R. P. et al. Long-duration Parkinson's disease: role of lateralization of motor features. Parkinsonism Relat. Disord. 19, 77-80 (2013).
8. Selikhova, M. et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 132, 2947-2957 (2009).
9. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
10. Beach, T. G. et al. Olfactory bulb alphasynucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 117, 169-174 (2009).
11. Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S. & Kordower, J. H. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov. Disord. 27, 716-719 (2012).
12. Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J. & Borghammer, P. Pathological alphasynuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79, 940-949 (2016).
13. Corbille, A. G. et al. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol. Commun. 4, 35 (2016).
14. Pouclet, H. et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol. Dis. 45, 305-309 (2012).
15. Beach, T. G. et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119, 689-702 (2010).
16. Visanji, N. P. et al. Colonic mucosal synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 84, 609-616 (2015).
17. Visanji, N. P., Marras, C., Hazrati, L. N., Liu, L. W. & Lang, A. E. Alimentary, my dear Watson? The challenges of enteric alpha-synuclein as a Parkinson's disease biomarker. Mov. Disord. 29, 444-450 (2014).
18. Gray, M. T., Munoz, D. G., Gray, D. A., Schlossmacher, M. G. & Woulfe, J. M. Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov. Disord. 29, 991-998 (2014).
19. Ling, H. et al. TDP?43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. Neurobiol. Aging 34, 2889e5-2889.e9 (2013).
20. Wider, C., Dickson, D. W. & Wszolek, Z. K. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener. Dis. 7, 175-179 (2010).
21. Marder, K. et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 85, 89-95 (2015).
22. Hague, K., Lento, P., Morgello, S., Caro, S. & Kaufmann, H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol. 94, 192-196 (1997).
23. Kaufmann, H. & Goldstein, D. S. Pure autonomic failure: a restricted Lewy body synucleinopathy or early Parkinson disease? Neurology 74, 536-537 (2010).
24. Donadio, V. et al. Skin nerve misfolded alpha-synuclein in pure autonomic failure and Parkinson disease. Ann. Neurol. 79, 306-316 (2016).
25. Iranzo, A. et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 9, e89741 (2014).
26. Postuma, R. B. et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72, 1296-1300 (2009).
27. Postuma, R. B., Gagnon, J. F., Vendette, M., Charland, K. & Montplaisir, J. REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. J. Neurol. Neurosurg. Psychiatry 79, 1117-1121 (2008).
28. Berg, D. et al. MDS research criteria for prodromal Parkinson's disease. Mov. Disord. 30, 1600-1611 (2015).
29. Stern, M. B., Lang, A. & Poewe, W. Toward a redefinition of Parkinson's disease. Mov. Disord. 27, 54-60 (2012).
30. Hawkes, C. H. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov. Disord. 23, 1799-1807 (2008).
31. AlDakheel, A., Kalia, L. V. & Lang, A. E. Pathogenesistargeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 11, 6-23 (2014).
32. Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184 (1992).
33. Park, A. & Stacy, M. Disease-modifying drugs in Parkinson's disease. Drugs 75, 2065-2071 (2015).
34. Crick, F. Central dogma of molecular biology. Nature 227, 561-563 (1970).
35. Osler, W. The Principles and Practice of Medicine: Designed for the Use of Practitioners and Students of Medicine (Young J. Putland, 1892).
36. Grocott, M. P. Integrative physiology and systems biology: reductionism, emergence and causality. Extrem. Physiol. Med. 2, 9 (2013).
37. Mullin, S. & Schapira, A. H. Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurol. Clin. 33, 1-17 (2015).
38. Franklin, S. & Vondriska, T. M. Genomes, proteomes, and the central dogma. Circ. Cardiovasc. Genet. 4, 576 (2011).
39. Kaddurah-Daouk, R. & Krishnan, K. R. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34, 173-186 (2009).
40. Edwards, L. M. & Thiele, I. Applying systems biology methods to the study of human physiology in extreme environments. Extrem. Physiol. Med. 2, 8 (2013).
41. Fujita, K. A. et al. Integrating pathways of Parkinson's disease in a molecular interaction map. Mol. Neurobiol. 49, 88-102 (2014).
42. Cholerton, B. et al. Precision medicine: clarity for the complexity of dementia. Am. J. Pathol. 186, 500-506 (2016).
43. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629-635 (2011).
44. Siderowf, A. et al. Impaired olfaction and other prodromal features in the Parkinson At?Risk Syndrome Study. Mov. Disord. 27, 406-412 (2012).
45. George, S. & Brundin, P. Immunotherapy in Parkinson's disease: micromanaging alpha-synuclein aggregation. J. Parkinsons Dis. 5, 413-424 (2015).
46. Dugger, B. N. et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat. Disord. 20, 525-529 (2014).
47. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321, 1364-1371 (1989).
48. Pajares, S., Arias, A., Garcia-Villoria, J., Briones, P. & Ribes, A. Role of creatine as biomarker of mitochondrial diseases. Mol. Genet. Metab. 108, 119-124 (2013).
49. Parkinson Study Group QE3 Investigators et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71, 543-552 (2014).
50. Snow, B. J. et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25, 1670-1674 (2010).
51. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313, 584-593 (2015).
52. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, doubleblind, randomised trial. Lancet Neurol. 14, 795-803 (2015).
53. Simon, D. K. et al. Peripheral biomarkers of Parkinson's disease progression and pioglitazone effects. J. Parkinsons Dis. 5, 731-736 (2015).
54. Rascol, O. et al. A 2-year multicenter, placebocontrolled, double-blind, parallel group study of the effect of riluzole on Parkinson's disease progression. Mov. Disord. 17, S39 (2002).
55. Shults, C. W. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. Acta Neurol. Scand. Suppl. 146, 36-42 (1993).
56. Myllyla, V. V., Sotaniemi, K. A., Vuorinen, J. A. & Heinonen, E. H. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42, 339-343 (1992).
57. Olanow, C. W. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268-1278 (2009).
58. Olanow, W. et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78, 248-257 (2015).
59. Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459-466 (2006).
60. Ribeiro, M. J., Stoessl, A. J. & Brooks, D. Evaluation of a potential neurotrophic drug on the progression of Parkinson disease with 18FDOPA. J. Nucl. Med. 50, A125 (2006).
61. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01060878 (2013).
62. NINDS NET?PD Investigators. A randomized, doubleblind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664-671 (2006).
63. Chen, H., O'Reilly, E. J., Schwarzschild, M. A. & Ascherio, A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 167, 90-95 (2008).
64. GPI 1485 Study Group. GPI 1485, a neuroimmunophilin ligand, fails to alter disease progression in mild to moderate Parkinson's disease. Mov. Disord. 21, A1009 (2006).
65. Olanow, C. W. et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 5, 1013-1020 (2006).
66. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP?1347 fails to delay disability in early Parkinson disease. Neurology 69, 1480-1490 (2007).
67. Albanese, A. et al. Phenomenology and classification of dystonia: a consensus update. Mov. Disord. 28, 863-873 (2013).